A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study

Although concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard treatment for patients with stage III non-small cell lung cancer (NSCLC), only half of the patients are allowed to receive CCRT in real-world settings. We evaluated the efficacy and safety of durvalumab after radiation monotherapy for NSCLC patients who are ineligible for chemoradiotherapy.

Source: European Journal of Cancer - October 9, 2023 Category: Cancer & Oncology Authors: Tadaaki Yamada, Yasuhiro Goto, Hiroshi Tanaka, Hideharu Kimura, Koichi Minato, Hiroshi Gyotoku, Takeshi Honda, Satoshi Watanabe, Kenji Morimoto, Fumiaki Kiyomi, Junji Uchino, Koichi Takayama Source Type: research